Incannex Healthcare (IXHL) Stock Price, News & Analysis

Company Overview

Incannex Healthcare Ltd is a clinical-stage biopharmaceutical company focused on developing novel therapies that combine cannabinoid and psychedelic compounds. Headquartered in Melbourne, Australia, with research operations in the United States, the company seeks to leverage the therapeutic potential of its proprietary formulations to address a range of medical conditions. Incannex is publicly traded on the NASDAQ under the ticker IXHL and maintains a presence in both Australia and North America.

The company’s research and development pipeline includes multiple product candidates in various stages of clinical evaluation. Lead programs target pulmonary hypertension, refractory epilepsy, and chronic cough, with formulations designed for inhalation delivery. In addition, Incannex is advancing studies in post-viral syndromes such as long COVID, exploring the anti-inflammatory and neuroprotective properties of its compounds. Preclinical work and early-phase trials have provided proof-of-concept data supporting further clinical investigation.

Incannex holds an expanding portfolio of patents covering its inhalation devices, formulation technologies and combination drug compositions. The company collaborates with contract research organizations and academic institutions to oversee regulatory filings, toxicology studies and pharmacokinetic assessments. By building a comprehensive intellectual property estate, Incannex aims to position itself for strategic partnerships or licensing agreements upon completion of pivotal trials.

Founded in 2017, Incannex has grown from a research start-up into a development-stage biotech enterprise. Its management team brings experience in drug development, regulatory affairs and commercial strategy, guiding the company through cross-listings on the Australian Securities Exchange and the NASDAQ. With clinical programs underway in Australia and the U.S., Incannex Healthcare is advancing toward proof-of-efficacy studies that could inform its pathway to market for novel cannabinoid-based therapeutics.

Key Stats

• Today's Range: $4.59 to $4.80
• 50-Day Range: $2.56 to $8.23
• 52-Week Range: $2.40 to $49.80
• Volume: 254,209 shs
• Average Volume: 490,756 shs
• Market Capitalization: $56.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Incannex Healthcare Stock Analysis - MarketRank™

Incannex Healthcare scored higher than 4% of companies evaluated by MarketBeat, and ranked 844th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Incannex Healthcare has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Incannex Healthcare has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Incannex Healthcare are expected to grow in the coming year, from ($2.10) to $0.90 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Incannex Healthcare is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Incannex Healthcare is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Incannex Healthcare has a P/B Ratio of 2.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.71% of the float of Incannex Healthcare has been sold short.

Short Interest Ratio / Days to Cover

Incannex Healthcare has a short interest ratio ("days to cover") of 1.92, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Incannex Healthcare has recently increased by 11.47%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Incannex Healthcare does not currently pay a dividend.

Dividend Growth

Incannex Healthcare does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 2 people have searched for IXHL on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.

MarketBeat Follows

4 people have added Incannex Healthcare to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Incannex Healthcare insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.33% of the stock of Incannex Healthcare is held by insiders.

Percentage Held by Institutions

0.43% of the stock of Incannex Healthcare is held by institutions.

IXHL Stock Analysis - Frequently Asked Questions

How have IXHL shares performed this year?

Incannex Healthcare's stock was trading at $10.74 at the start of the year. Since then, IXHL stock has decreased by 55.8% and is now trading at $4.75.

How were Incannex Healthcare's earnings last quarter?

Incannex Healthcare Inc. (NASDAQ:IXHL) posted its earnings results on Friday, February, 13th. The company reported ($0.02) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.02).

When did Incannex Healthcare's stock split?

Incannex Healthcare's stock reverse split on Friday, February 27th 2026.The 1-30 reverse split was announced on Wednesday, February 25th 2026. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 26th 2026. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of Incannex Healthcare?

Shares of IXHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Incannex Healthcare own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Incannex Healthcare investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), e.l.f. Beauty (ELF), Disc Medicine (IRON) and Jabil (JBL).

Company Calendar

• Last Earnings: 2/13/2026
• Today: 5/05/2026
• Next Earnings (Estimated): 5/14/2026
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IXHL
• CIK: 1873875
• Web: impression.healthcare
• Phone: 425-703-805
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($8.41)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$46.88 million
• Net Margins: N/A
• Pretax Margin: -398,933.31%
• Return on Equity: -114.95%
• Return on Assets: -103.38%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 48.27
• Quick Ratio: 48.27

Sales & Book Value

• Annual Sales: $90 thousand
• Price / Sales: 629.64
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.07 per share
• Price / Book: 2.29

Miscellaneous

• Outstanding Shares: 11,930,000
• Free Float: 11,773,000
• Market Cap: $56.67 million
• Optionable: Not Optionable
• Beta: 7.22